Gilead Sciences is co-leading a $75m PIPE deal for the coronavirus drug developer, which is set take the place on Nasdaq held by FS Development Corp II later this year.

US-based oral antiviral therapy developer Pardes Biosciences agreed a reverse takeover yesterday with $75m in private investment in public equity (PIPE) financing co-led by biopharmaceutical firm Gilead Sciences.

The company is set to merge with special purpose acquisition company FS Development Corp II, which listed on the Nasdaq Capital Market in a $115m initial public offering in January this year.

Foresite Capital, the investment firm affiliated with FS Development Corp II, is co-leading the PIPE with Gilead, Frazier Life…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn